Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells

Cell Death and Disease

Volumn 5, Issue 7, 2014, Pages

  Yan, J ^a,b,c   Zhong, N ^a,b,c   Liu, G ^a   Chen, K ^b   Liu, X ^a   Su, L ^a   Singha, S ^c  

^a SHANDONG UNIVERSITY   (China)

^b Central Hospital of Shandong Xinwen   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ACTIVATING TRANSCRIPTION FACTOR 4; DEUBIQUITINASE; MYELOID LEUKEMIA FACTOR 1; PEMETREXED; PEPTIDASE; PROTEIN BCL 2; PROTEIN NOXA; SMALL INTERFERING RNA; UBIQUITIN SPECIFIC PEPTIDASE 9X; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; MCL1 PROTEIN, HUMAN; PMAIP1 PROTEIN, HUMAN; PROTEIN MCL 1; UBIQUITIN THIOLESTERASE; USP9X PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; GENE SEQUENCE; HISTONE UBIQUITINATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; UBIQUITIN THIOLESTERASE;

EID: 84905492796     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.281     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29
3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551
4. Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA et al. bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 1993; 53: 3321-3326
5. Jackson RC. Biological effects of folic acid antagonists with antineoplastic activity. Pharmacol Ther 1984; 25: 61-82
6. Schultz RM. Newer antifolates in cancer therapy. Prog Drug Res 1995; 44: 129-157
7. Ramirez JM, Ocio EM, San Miguel JF, Pandiella A. Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. Leukemia 2007; 21: 797-804
8. McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW et al. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res 2000; 6: 2677-2684
9. Lu X, Errington J, Curtin NJ, Lunec J, Newell DR. The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res 2001; 7: 2114-2123
10. Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C et al. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 1997; 39: 521-531
11. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116-1123
12. Su L, Liu G, Hao X, Zhong N, Zhong D, Liu X et al. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. Eur J Cancer 2011; 47: 2471-2478
13. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009; 9: 501-507
14. Huang DC, Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000; 103: 839-842
15. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 2007; 129: 1337-1349
16. Shibue T, Taniguchi T. BH3-only proteins: integrated control point of apoptosis. Int J Cancer 2006; 119: 2036-2043
17. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403
18. Mei Y, Xie C, Xie W, Tian X, Li M, Wu M. Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis. Neoplasia 2007; 9: 871-881
19. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011; 20: 1397-1411
20. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003; 17: 1475-1486
21. Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W. Mcl-1 ubiquitination and destruction. Oncotarget 2011; 2: 239-244
22. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463: 103-107
23. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci USA 2009; 106: 2200-2205
24. Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta 2013; 1833: 3460-3470
25. Kawabata S, Gills JJ, Mercado-Matos JR, Lopiccolo J, Wilson W 3rd, Hollander MC et al. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis 2012; 3: e353
26. Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038
27. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 2011; 30: 1963-1968
28. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DC et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 2007; 104: 6217-6222
29. Gomez-Bougie P, Ménoret E, Juin P, Dousset C, Pellat-Deceunynck C, Amiot M. Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction. Biochem Biophys Res Commun 2011; 413: 460-464
30. Backus HH, Pinedo HM, Wouters D, Kuiper CM, Jansen G, van Groeningen CJ et al. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. Oncol Res 2000; 12: 231-239
31. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004; 96: 1769-1780
32. Liu G, Su L, Hao X, Zhong N, Zhong D, Singhal S et al. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J Cell Mol Med 2012; 16: 1618-1628